{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:04:12Z","timestamp":1783937052341,"version":"3.55.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T00:00:00Z","timestamp":1419292800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00520-014-2525-4","type":"journal-article","created":{"date-parts":[[2014,12,22]],"date-time":"2014-12-22T01:42:07Z","timestamp":1419212527000},"page":"1157-1168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents"],"prefix":"10.1007","volume":"23","author":[{"given":"Donald L.","family":"Patrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Cleeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"von Moos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Fallowfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"\u00d6hrling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,23]]},"reference":[{"key":"2525_CR1","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s\u20136249s","journal-title":"Clin Cancer Res"},{"key":"2525_CR2","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1016\/j.ejca.2009.05.024","volume":"45","author":"K Harris","year":"2009","unstructured":"Harris K, Chow E, Zhang L, Velikova G, Bezjak A, Wu J, Barton M, Sezer O, Eek R, Shafiq J, Yee A, Clemons M, Brundage M, Hoskin P, van der Linden Y, Johnson CD, Bottomley A, Group EQoL (2009) Patients\u2019 and health care professionals\u2019 evaluation of health-related quality of life issues in bone metastases. Eur J Cancer 45:2510\u20132518","journal-title":"Eur J Cancer"},{"key":"2525_CR3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.lungcan.2009.08.020","volume":"67","author":"C Langer","year":"2010","unstructured":"Langer C, Hirsh V (2010) Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates. Lung Cancer 67:4\u201311","journal-title":"Lung Cancer"},{"key":"2525_CR4","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588\u20131594","journal-title":"Cancer"},{"key":"2525_CR5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","volume":"9","author":"RE Coleman","year":"2004","unstructured":"Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9:14\u201327","journal-title":"Oncologist"},{"key":"2525_CR6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","volume":"16","author":"KP Weinfurt","year":"2005","unstructured":"Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, Schulman KA (2005) The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16:579\u2013584","journal-title":"Ann Oncol"},{"key":"2525_CR7","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1200\/JCO.2011.39.2381","volume":"30","author":"MJ Fisch","year":"2012","unstructured":"Fisch MJ, Lee JW, Weiss M, Wagner LI, Chang VT, Cella D, Manola JB, Minasian LM, McCaskill-Stevens W, Mendoza TR, Cleeland CS (2012) Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol 30:1980\u20131988","journal-title":"J Clin Oncol"},{"key":"2525_CR8","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/annonc\/mdn419","volume":"19","author":"S Deandrea","year":"2008","unstructured":"Deandrea S, Montanari M, Moja L, Apolone G (2008) Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 19:1985\u20131991","journal-title":"Ann Oncol"},{"key":"2525_CR9","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/sj.bjc.6605053","volume":"100","author":"G Apolone","year":"2009","unstructured":"Apolone G, Corli O, Caraceni A, Negri E, Deandrea S, Montanari M, Greco MT, Cancer Pain Outcome Research Study Group I (2009) Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research study group. Br J Cancer 100:1566\u20131574","journal-title":"Br J Cancer"},{"key":"2525_CR10","unstructured":"World Health Organization (1996) Cancer pain relief. With a guide to opioid availability, 2nd edition. Geneva, Switzerland"},{"key":"2525_CR11","doi-asserted-by":"crossref","first-page":"vii139","DOI":"10.1093\/annonc\/mds233","volume":"23","author":"CI Ripamonti","year":"2012","unstructured":"Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F, Group EGW (2012) Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol 23:vii139\u2013154","journal-title":"Ann Oncol"},{"key":"2525_CR12","unstructured":"National Comprehensive Cancer Network (2013) NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae). Non-small cell lung cancer. Version 2.2013. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/nscl.pdf . Accessed 19 Sept 2013"},{"key":"2525_CR13","doi-asserted-by":"crossref","unstructured":"Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G, European Palliative Care Research Collaborative (EPCRC), European Association for Palliative Care (EAPC) (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58\u201368","DOI":"10.1016\/S1470-2045(12)70040-2"},{"key":"2525_CR14","unstructured":"National Comprehensive Cancer Network (2014) NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae). Adult cancer pain version 2.2014. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pain.pdf . Accessed 19 June 2014"},{"key":"2525_CR15","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813\u2013822","journal-title":"Lancet"},{"key":"2525_CR16","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132\u20135139","journal-title":"J Clin Oncol"},{"key":"2525_CR17","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125\u20131132","journal-title":"J Clin Oncol"},{"key":"2525_CR18","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1093\/annonc\/mds175","volume":"23","author":"S Vadhan-Raj","year":"2012","unstructured":"Vadhan-Raj S, von Moos R, Fallowfield LJ, Patrick DL, Goldwasser F, Cleeland CS, Henry DH, Novello S, Hungria V, Qian Y, Feng A, Yeh H, Chung K (2012) Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol 23:3045\u20133051","journal-title":"Ann Oncol"},{"key":"2525_CR19","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458\u20131468","journal-title":"J Natl Cancer Inst"},{"key":"2525_CR20","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3816\/CGC.2007.n.022","volume":"5","author":"F Saad","year":"2007","unstructured":"Saad F, Chen YM, Gleason DM, Chin J (2007) Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 5:390\u2013396","journal-title":"Clin Genitourin Cancer"},{"key":"2525_CR21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100:36\u201343","journal-title":"Cancer"},{"key":"2525_CR22","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","volume":"23","author":"N Kohno","year":"2005","unstructured":"Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314\u20133321","journal-title":"J Clin Oncol"},{"key":"2525_CR23","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00520-008-0487-0","volume":"16","author":"R Moos von","year":"2008","unstructured":"von Moos R, Strasser F, Gillessen S, Zaugg K (2008) Metastatic bone pain: treatment options with an emphasis on bisphosphonates. Support Care Cancer 16:1105\u20131115","journal-title":"Support Care Cancer"},{"key":"2525_CR24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.17925\/EOH.2012.08.3.148","volume":"8","author":"L Fallowfield","year":"2012","unstructured":"Fallowfield L, von Moos R, Costa L, Stopeck A, Clemons M, Clarke N, Braun A, Chung K (2012) Weighing bone-targeted treatment options for patients with solid tumours and skeletal complications from metastatic disease. Eur Oncol Haematol 8:148\u2013155","journal-title":"Eur Oncol Haematol"},{"key":"2525_CR25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","volume":"9","author":"RH Dworkin","year":"2008","unstructured":"Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J, Zavisic S (2008) Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9:105\u2013121","journal-title":"J Pain"},{"key":"2525_CR26","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.27789","volume":"119","author":"CS Cleeland","year":"2013","unstructured":"Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT, Qian Y, Jiang Q, Dansey R, Braun A, Chung K (2013) Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer 119:832\u2013838","journal-title":"Cancer"},{"key":"2525_CR27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/pme.12299","volume":"15","author":"KC Chung","year":"2014","unstructured":"Chung KC, Barlev A, Braun AH, Qian Y, Zagari M (2014) Assessing analgesic use in patients with advanced cancer: development of a new scale\u2014the Analgesic Quantification Algorithm. Pain Med 15:225\u2013232","journal-title":"Pain Med"},{"key":"2525_CR28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.suponc.2010.12.004","volume":"9","author":"SD Mathias","year":"2011","unstructured":"Mathias SD, Crosby RD, Qian Y, Jiang Q, Dansey R, Chung K (2011) Estimating minimally important differences for the worst pain rating of the brief pain inventory-short form. J Support Oncol 9:72\u201378","journal-title":"J Support Oncol"},{"key":"2525_CR29","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1470-2045(13)70424-8","volume":"14","author":"E Basch","year":"2013","unstructured":"Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, Molina A, Cleeland C (2013) Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol 14:1193\u20131199","journal-title":"Lancet Oncol"},{"key":"2525_CR30","doi-asserted-by":"crossref","first-page":"6236s","DOI":"10.1158\/1078-0432.CCR-06-0988","volume":"12","author":"CS Cleeland","year":"2006","unstructured":"Cleeland CS (2006) The measurement of pain from metastatic bone disease: capturing the patient\u2019s experience. Clin Cancer Res 12:6236s\u20136242s","journal-title":"Clin Cancer Res"},{"key":"2525_CR31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00520-011-1356-9","volume":"20","author":"LS Matza","year":"2012","unstructured":"Matza LS, Fallowfield LJ, Chung KC, Currie BM, Van Brunt K, Patrick DL (2012) Patient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastases. Support Care Cancer 20:657\u2013677","journal-title":"Support Care Cancer"},{"key":"2525_CR32","doi-asserted-by":"crossref","unstructured":"Brown JE, Cleeland CS, Fallowfield LJ, Patrick DL, Fizazi K, Smith MR, Maroto JP, Michel MS, Feng A, Goessl C, Chung K (2011) Pain outcomes in patients with bone metastases from castrate-resistant prostate cancer: results from a phase 3 trial of denosumab vs. zoledronic acid [abstract #1091]. Presented at: 26th Annual EAU Congress, Vienna, Austria","DOI":"10.1016\/S1569-9056(11)61070-1"},{"key":"2525_CR33","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1016\/j.juro.2011.02.1679","volume":"185","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Cleeland C, Fallowfield L, Smith MR, Trachtenberg J, Chilingirov P, Michel MS, Oudard S, Feng A, Chung K (2011) Effects of denosumab and zoledronic acid on pain interference with daily functioning in patients with castrate-resistant prostate cancer [abstract #711]. J Urol 185:e286","journal-title":"J Urol"},{"key":"2525_CR34","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","volume":"335","author":"GN Hortobagyi","year":"1996","unstructured":"Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer study group. N Engl J Med 335:1785\u20131791","journal-title":"N Engl J Med"},{"key":"2525_CR35","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","volume":"16","author":"GN Hortobagyi","year":"1998","unstructured":"Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer study group. J Clin Oncol 16:2038\u20132044","journal-title":"J Clin Oncol"},{"key":"2525_CR36","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","volume":"17","author":"RL Theriault","year":"1999","unstructured":"Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer study group. J Clin Oncol 17:846\u2013854","journal-title":"J Clin Oncol"},{"key":"2525_CR37","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","volume":"14","author":"JJ Body","year":"2003","unstructured":"Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergstrom B, Group MFS (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399\u20131405","journal-title":"Ann Oncol"},{"key":"2525_CR38","doi-asserted-by":"crossref","unstructured":"Diel IJ, Body JJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergstr\u00f6m B, MF 4265 Study Group (2004) Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40:1704\u20131712","DOI":"10.1016\/j.ejca.2004.03.025"},{"key":"2525_CR39","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","volume":"111","author":"JJ Body","year":"2004","unstructured":"Body JJ, Diel IJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazarev AF, Tripathy D, Bergstr\u00f6m B (2004) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111:306\u2013312","journal-title":"Pain"},{"key":"2525_CR40","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000338369","volume":"35","author":"K Altundag","year":"2012","unstructured":"Altundag K, Dizdar O, Ozsaran Z, Ozkok S, Saip P, Eralp Y, Komurcu S, Kuzhan O, Ozguroglu M, Karahoca M (2012) Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain. Onkologie 35:254\u2013258","journal-title":"Onkologie"},{"key":"2525_CR41","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2003.03.042","volume":"21","author":"DS Ernst","year":"2003","unstructured":"Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W (2003) Randomized, double-blind, controlled trial of mitoxantrone\/prednisone and clodronate versus mitoxantrone\/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21:3335\u20133342","journal-title":"J Clin Oncol"},{"key":"2525_CR42","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100:2613\u20132621","journal-title":"Cancer"},{"key":"2525_CR43","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/annonc\/mdl041","volume":"17","author":"KP Weinfurt","year":"2006","unstructured":"Weinfurt KP, Anstrom KJ, Castel LD, Schulman KA, Saad F (2006) Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol 17:986\u2013989","journal-title":"Ann Oncol"},{"key":"2525_CR44","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.bjc.6602551","volume":"92","author":"A Wardley","year":"2005","unstructured":"Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92:1869\u20131876","journal-title":"Br J Cancer"},{"key":"2525_CR45","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377\u2013387","journal-title":"Cancer J"},{"key":"2525_CR46","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1634\/theoncologist.11-7-841","volume":"11","author":"G Carten\u00ec","year":"2006","unstructured":"Carten\u00ec G, Bordonaro R, Giotta F, Lorusso V, Scalone S, Vinaccia V, Rondena R, Amadori D (2006) Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Oncologist 11:841\u2013848","journal-title":"Oncologist"},{"key":"2525_CR47","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3816\/SCT.2007.n.016","volume":"4","author":"A Kretzschmar","year":"2007","unstructured":"Kretzschmar A, Wiegel T, Al-Batran SE, Hinrichs H, Kindler M, Steck T, Illiger H, Heinemann V, Schmidt K, Haus U, Kirner A, Ehninger G (2007) Rapid and sustained influence of intravenous zoledronic acid on course of pain and analgesics consumption in patients with cancer with bone metastases: a multicenter open-label study over 1 year. Support Cancer Ther 4:203\u2013210","journal-title":"Support Cancer Ther"},{"key":"2525_CR48","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1158\/1078-0432.CCR-11-3310","volume":"18","author":"M Martin","year":"2012","unstructured":"Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, Fallowfield L, Fujiwara Y, Jassem J, Paterson AH, Ritchie D, Steger GG, Stopeck A, Vogel C, Fan M, Jiang Q, Chung K, Dansey R, Braun A (2012) Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res 18:4841\u20134849","journal-title":"Clin Cancer Res"},{"key":"2525_CR49","unstructured":"Patrick D, Cleeland C, Fallowfield L, Smith M, Klotz L, Oudard S, Marx G, Wei R, \u00d6hrling K, Qian Y (2014) Denosumab or zoledronic acid (ZA) therapy on pain interference and cancer-specific quality of life (CSQoL) in patients with castrate-resistant prostate cancer (CRPC) and bone metastases (BM) [abstract accepted]. Presented at: 2014 Genitourinary Cancers Symposium; January 30-February 1, 2014; San Francisco, CA"},{"key":"2525_CR50","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00520-013-2022-1","volume":"22","author":"D Henry","year":"2014","unstructured":"Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, Jun S, Dansey R, Yeh H (2014) Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer 22:679\u2013687","journal-title":"Support Care Cancer"},{"key":"2525_CR51","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1007\/s00520-013-1932-2","volume":"21","author":"R Moos von","year":"2013","unstructured":"von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL, Palazzo FG, Qian Y, Braun A, Chung K (2013) Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer 21:3497\u20133507","journal-title":"Support Care Cancer"},{"key":"2525_CR52","doi-asserted-by":"crossref","unstructured":"Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, Howell D, Konski A, Kachnic L, Lo S, Sahgal A, Silverman L, von Gunten C, Mendel E, Vassil A, Bruner DW, Hartsell W, American Society for Radiation Oncology (ASTRO) (2011) Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 79:965\u2013976","DOI":"10.1016\/j.ijrobp.2010.11.026"},{"key":"2525_CR53","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1200\/JCO.2006.09.5281","volume":"25","author":"E Chow","year":"2007","unstructured":"Chow E, Harris K, Fan G, Tsao M, Sze WM (2007) Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 25:1423\u20131436","journal-title":"J Clin Oncol"},{"key":"2525_CR54","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0305-7372(03)00013-6","volume":"29","author":"P Hoskin","year":"2003","unstructured":"Hoskin P (2003) Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev 29:321\u2013327","journal-title":"Cancer Treat Rev"},{"key":"2525_CR55","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00520-009-0663-x","volume":"18","author":"L Atahan","year":"2010","unstructured":"Atahan L, Yildiz F, Cengiz M, Kaplan B, Ozkan M, Yazici G, G\u00fcndo\u011f M, Haydaro\u011flu A, Korcum AF, Seng\u00f6z M, Din\u00e7er M, Akmansu M, Engin K, Hayran M (2010) Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study. Support Care Cancer 18:691\u2013698","journal-title":"Support Care Cancer"},{"key":"2525_CR56","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12094-008-0198-5","volume":"10","author":"A Ma\u00f1as","year":"2008","unstructured":"Ma\u00f1as A, Casas F, Ciria JP, L\u00f3pez C, S\u00e1ez J, Palacios A, de las Heras M, Porto C, S\u00e1nchez E, Mart\u00edn C, Esco R, Veiras C, Mart\u00ednez JC, M\u00e1rquez M, Ramos A, Calvo F, Fuertes J, Andreu FJ, Contreras J, P\u00e9rez L, Romero J, Vayreda J, Victoria C (2008) Randomised study of single dose (8 Gy vs. 6 Gy) of analgesic radiotherapy plus zoledronic acid in patients with bone metastases. Clin Transl Oncol 10:281\u2013287","journal-title":"Clin Transl Oncol"},{"key":"2525_CR57","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s00776-012-0294-9","volume":"17","author":"N Takeda","year":"2012","unstructured":"Takeda N, Isu K, Hiraga H, Shinohara N, Minami A, Kamata H (2012) Zoledronic acid enhances the effect of radiotherapy for bone metastases from renal cell carcinomas: more than a 24-month median follow-up. J Orthop Sci 17:770\u2013774","journal-title":"J Orthop Sci"},{"key":"2525_CR58","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1464-410X.2008.08124.x","volume":"103","author":"T Kijima","year":"2009","unstructured":"Kijima T, Fujii Y, Suyama T, Okubo Y, Yamamoto S, Masuda H, Yonese J, Fukui I (2009) Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int 103:620\u2013624","journal-title":"BJU Int"},{"key":"2525_CR59","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0959-8049(11)70106-X","volume":"47","author":"P Hoskin","year":"2011","unstructured":"Hoskin P, Sundar S, Reczko K (2011) A multicenter randomized trial of ibandronate compared to single dose radiotherapy for localized metastatic bone pain in prostate cancer (RIB) [abstract 7LBA]. Eur J Cancer 47:6","journal-title":"Eur J Cancer"},{"key":"2525_CR60","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijrobp.2006.08.022","volume":"67","author":"V Vassiliou","year":"2007","unstructured":"Vassiliou V, Kalogeropoulou C, Christopoulos C, Solomou E, Leotsinides M, Kardamakis D (2007) Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. Int J Rad Oncol Biol Phys 67:264\u2013272","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"2525_CR61","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10585-007-9066-x","volume":"24","author":"V Vassiliou","year":"2007","unstructured":"Vassiliou V, Kalogeropoulou C, Giannopoulou E, Leotsinidis M, Tsota I, Kardamakis D (2007) A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate. Clin Exp Metastasis 24:169\u2013178","journal-title":"Clin Exp Metastasis"},{"key":"2525_CR62","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/107327481201900208","volume":"19","author":"M Tomblyn","year":"2012","unstructured":"Tomblyn M (2012) The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases. Cancer Control 19:137\u2013144","journal-title":"Cancer Control"},{"key":"2525_CR63","unstructured":"Roque IFM, Martinez-Zapata MJ, Scott-Brown M, Alonso-Coello P (2011) Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev:CD003347"},{"key":"2525_CR64","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1007\/s00259-007-0659-z","volume":"35","author":"MG Lam","year":"2008","unstructured":"Lam MG, Dahmane A, Stevens WH, van Rijk PP, de Klerk JM, Zonnenberg BA (2008) Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eur J Nucl Med Mol Imaging 35:756\u2013765","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2525_CR65","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bone.2005.12.004","volume":"39","author":"G Storto","year":"2006","unstructured":"Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L, Salvatore M (2006) Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 39:35\u201341","journal-title":"Bone"},{"key":"2525_CR66","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1200\/jco.2013.31.6_suppl.19","volume":"31","author":"S Nilsson","year":"2013","unstructured":"Nilsson S, Sartor AO, Bruland OS, Fang F, Aksnes A-K, Parker C (2013) Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases. J Clin Oncol 31:5038","journal-title":"J Clin Oncol"},{"key":"2525_CR67","doi-asserted-by":"crossref","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall\u2019Oglio M, Franzen L, Coleman R, Vogelzang NJ, O\u2019Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O, ALSYMPCA Investigators (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213\u2013223","DOI":"10.1056\/NEJMoa1213755"},{"key":"2525_CR68","unstructured":"Coleman R, Fossa S, Chodacki A, Wedel S, Bruland O, Staudacher K, Garcia-Vargas J, Sartor O (2013) Time to first skeletal-related event (SRE) with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases: ALSYMPCA trial stratification factors analysis [abstract #2876]. Presented at: European Cancer Congress; Sept 27-Oct 1, 2013; Amsterdam, Netherlands"},{"key":"2525_CR69","unstructured":"National Comprehensive Cancer Network (2013) NCCN clinical practice guidelines in oncology (NCCN Guidelines\u2122). Prostate cancer. Version 4.2013. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/prostate.pdf . Accessed 19 Sept 2013"},{"key":"2525_CR70","unstructured":"National Comprehensive Cancer Network (2013) NCCN clinical practice guidelines in oncology (NCCN Guidelines\u2122). Breast cancer. Version 3.2013. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/breast.pdf . Accessed 19 Sept 2013"},{"key":"2525_CR71","unstructured":"National Comprehensive Cancer Network (2013) NCCN clinical practice guidelines in oncology (NCCN Guidelines\u2122). Thyroid carcinoma. Version 2.2013. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/thyroid.pdf . Accessed 19 Sept 2013"},{"key":"2525_CR72","unstructured":"National Comprehensive Cancer Network (2013) NCCN clinical practice guidelines in oncology (NCCN Guidelines\u2122). Kidney cancer. Version 1.2013. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf . Accessed 19 Sept 2013"},{"key":"2525_CR73","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/j.juro.2012.02.1041","volume":"187","author":"D Patrick","year":"2012","unstructured":"Patrick D, Cleeland C, Fallowfield L, Smith M, Trachtenberg J, Oudard S, Feng A, Goessl C, Chung K (2012) Pain interference with daily functioning in patients with castrate-resistant prostate cancer: a comparison of denosumab and zoledronic acid [abstract #943]. J Urol 187:e384","journal-title":"J Urol"},{"key":"2525_CR74","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijrobp.2011.10.080","volume":"84","author":"M Huisman","year":"2012","unstructured":"Huisman M, van den Bosch MA, Wijlemans JW, van Vulpen M, van der Linden YM, Verkooijen HM (2012) Effectiveness of reirradiation for painful bone metastases: a systematic review and meta-analysis. Int J Rad Oncol Biol Phys 84:8\u201314","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"2525_CR75","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10147-012-0414-8","volume":"18","author":"L Costa","year":"2013","unstructured":"Costa L, Lipton A, Hadji P, Chen YM, Kosmidis P (2013) Treatment of bone metastases before the onset of pain. Int J Clin Oncol 18:531\u2013538","journal-title":"Int J Clin Oncol"},{"key":"2525_CR76","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1200\/jco.2011.29.15_suppl.4520","volume":"20","author":"C Logothetis","year":"2011","unstructured":"Logothetis C, De Bono JS, Molina A, Basch EM, Fizazi K, North SA, Chi K, Jones RJ, Goodman OB, Mainwaring P, Sternberg CN, Gagnon DD, Dhawan R, Hao Y, Liu CS, Kheoh T, Scher HI, Haqq CM (2011) Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): results from the COU-AA-301 phase III study. J Clin Oncol 20:4520","journal-title":"J Clin Oncol"},{"key":"2525_CR77","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S1470-2045(12)70473-4","volume":"13","author":"CJ Logothetis","year":"2012","unstructured":"Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS (2012) Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 13:1210\u20131217","journal-title":"Lancet Oncol"},{"key":"2525_CR78","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fl\u00e9chon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, Investigators A (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187\u20131197","journal-title":"N Engl J Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-014-2525-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-014-2525-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-014-2525-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T13:43:06Z","timestamp":1566135786000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-014-2525-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,23]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["2525"],"URL":"https:\/\/doi.org\/10.1007\/s00520-014-2525-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,23]]}}}